Read by QxMD icon Read

Marzouka G

Abdulla A Damluji, Conrad Macon, Arieh Fox, Grettel Garcia, Mohammed S Al-Damluji, George R Marzouka, Robert J Myerburg, Ian C Gilchrist, Mauricio G Cohen, Mauro Moscucci
INTRODUCTION: The effect of acute changes of hemoglobin during index heart failure admission on long-term outcomes remains unknown. METHODS: We examined 433 patients enrolled in the ESCAPE trial. RESULTS: Of the 433 patients, 324 (75%) had baseline and discharge hemoglobin available for analysis. Of those, 64 (20%) had at least 1g/dL drop of hemoglobin by time of discharge. Compared to patients without hemoglobin changes (g/dL), patients with hemoglobin drop were older (59 vs...
November 1, 2016: International Journal of Cardiology
Flora Peyvandi, Pier M Mannucci, Isabella Garagiola, Amal El-Beshlawy, Mohsen Elalfy, Vijay Ramanan, Peyman Eshghi, Suresh Hanagavadi, Ramabadran Varadarajan, Mehran Karimi, Mamta V Manglani, Cecil Ross, Guy Young, Tulika Seth, Shashikant Apte, Dinesh M Nayak, Elena Santagostino, Maria Elisa Mancuso, Adriana C Sandoval Gonzalez, Johnny N Mahlangu, Santiago Bonanad Boix, Monica Cerqueira, Nadia P Ewing, Christoph Male, Tarek Owaidah, Veronica Soto Arellano, Nathan L Kobrinsky, Suvankar Majumdar, Rosario Perez Garrido, Anupam Sachdeva, Mindy Simpson, Mathew Thomas, Ezio Zanon, Bulent Antmen, Kaan Kavakli, Marilyn J Manco-Johnson, Monica Martinez, Esperanza Marzouka, Maria G Mazzucconi, Daniela Neme, Angeles Palomo Bravo, Rogelio Paredes Aguilera, Alessandra Prezotti, Klaus Schmitt, Brian M Wicklund, Bulent Zulfikar, Frits R Rosendaal
BACKGROUND: The development of neutralizing anti-factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy. METHODS: We conducted a randomized trial to assess the incidence of factor VIII inhibitors among patients treated with plasma-derived factor VIII containing von Willebrand factor or recombinant factor VIII. Patients who met the eligibility criteria (male sex, age <6 years, severe hemophilia A, and no previous treatment with any factor VIII concentrate or only minimal treatment with blood components) were included from 42 sites...
May 26, 2016: New England Journal of Medicine
Abdulla A Damluji, Mohammed S Al-Damluji, George R Marzouka, James O Coffey, Juan F Viles-Gonzalez, Mauricio G Cohen, Mauro Moscucci, Robert J Myerburg, Raul D Mitrani
BACKGROUND: There are limited data on prognosis and outcomes of patients with new-onset atrial fibrillation (AF) compared with those with a prior history of AF. METHODS AND RESULTS: We conducted a comparison of these 2 groups in the AFFIRM trial. New-onset AF was the qualifying arrhythmia in 1,391 patients (34%). Compared with patients with prior history of AF, patients with new-onset AF were more likely to have a history of heart failure. There was no mortality difference between rate control (RaC) and rhythm control (RhC) among patients with new-onset AF (17% vs 20%, P = ...
July 2015: American Heart Journal
Abdulla A Damluji, Archana Ramireddy, Mohammed S Al-Damluji, George R Marzouka, Lynda Otalvaro, Juan F Viles-Gonzalez, Chunming Dong, Carlos E Alfonso, Robert C Hendel, Mauricio G Cohen, Mauro Moscucci, Nanette H Bishopric, Robert J Myerburg
INTRODUCTION: Based upon evidence suggesting that concentrations of anti-heat shock protein-60 (anti-HSP60) and interleukin-2 (IL-2) are associated with atherogenesis, we tested the hypothesis that anti-HSP60 and IL-2 are associated with coronary artery calcium (CAC) score, a marker of subclinical atherosclerosis. METHODS: We evaluated 998 asymptomatic adults, age 45-84 years, without known coronary disease from the Multi-Ethnic Study of Atherosclerosis (MESA), who had anti-HSP60 measured at baseline...
March 2015: Heart: Official Journal of the British Cardiac Society
Apurva O Badheka, Nileshkumar J Patel, Peeyush M Grover, Neeraj Shah, Vikas Singh, Abhishek Deshmukh, Kathan Mehta, Ankit Chothani, Michael Hoosien, Ankit Rathod, Ghanshyambhai T Savani, George R Marzouka, Sandeep Gupta, Raul D Mitrani, Mauro Moscucci, Mauricio G Cohen
Electrocardiographic lead aVR is often ignored in clinical practice. The aim of this study was to investigate whether ST-T wave amplitude in lead aVR predicts cardiovascular (CV) mortality and if this variable adds value to a traditional risk prediction model. A total of 7,928 participants enrolled in the National Health and Nutrition Examination Survey (NHANES) III with electrocardiographic data available were included. Each participant had 13.5 ± 3.8 years of follow-up. The study sample was stratified according to ST-segment amplitude and T-wave amplitude in lead aVR...
September 15, 2013: American Journal of Cardiology
Apurva O Badheka, Nileshkumar Patel, Tushar A Tuliani, Ankit Rathod, George R Marzouka, Sandip Zalawadiya, Abhishek Deshmukh, Mauro Moscucci, Mauricio G Cohen
BACKGROUND: We aimed to assess the additive value of electrocardiogram (ECG) findings to risk prediction models for cardiovascular disease. METHODS: Our dataset consisted of 6025 individuals with ECG data available from the National Health and Nutrition Examination Survey-III. This is a self-weighting sample with a follow-up of 79,046.84 person-years. The primary outcomes were cardiovascular mortality and all-cause mortality. We compared 2 models: Framingham Risk Score (FRS) covariates (Model A) and ECG abnormalities added to Model A (Model B), and calculated the net reclassification improvement index (NRI)...
April 2013: American Journal of Medicine
Apurva O Badheka, Ankit Rathod, George R Marzouka, Nileshkumar Patel, Syed S I Bokhari, Mauro Moscucci, Mauricio G Cohen
Most clinicians regard isolated, minor, or nonspecific ST-segment and T-wave (NS-STT) abnormalities to be incidental, often transient, and benign findings in asymptomatic patients. We sought to evaluate whether isolated NS-STT abnormalities on routine electrocardiograms (ECGs) are associated with increased risk of cardiovascular mortality (CM) and all-cause mortality (AM) in a cross-sectional United States population without known coronary artery disease. We included all adults 40 to 90 years of age without known coronary artery disease or risk equivalent based on history and laboratory values, enrolled in the NHANES III from 1988 to 1994, with electrocardiographic data available, and a total follow-up period of 59,781...
August 15, 2012: American Journal of Cardiology
D Mezzano, E Aranda, G Grebe, M E Legues, S Rodríguez, E Marzouka, E Ríos
No abstract text is available yet for this article.
November 1983: Revista Médica de Chile
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"